Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne H Hobbelt

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 9, 2017
Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND studyAnne H Hobbelt, Joylene E Siland, Bastiaan Geelhoed, et al.
European Heart Journal|March 23, 2017
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERTIsabelle C Van Gelder, Jeff S Healey, Harry J G M Crijns, et al.
International Journal of Cardiology. Heart & Vasculature|November 30, 2020
Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation - Data from the RACE 3 studyBao Oanh Nguyen, E P J Petra Wijtvliet, Anne H Hobbelt, et al.
European Heart Journal|February 6, 2018
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trialMichiel Rienstra, Anne H Hobbelt, Marco Alings, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 18, 2021
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trialBao Oanh Nguyen, Harry J G M Crijns, Jan G P Tijssen, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 26, 2021
Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 studyMeelad I H Al-Jazairi, Bao-Oanh Nguyen, Ruben R De With, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|January 11, 2019
Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 studyRuben R De With, Michiel Rienstra, Marcelle D Smit, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 9, 2017
Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND studyAnne H Hobbelt, Joylene E Siland, Bastiaan Geelhoed, et al.
European Heart Journal|March 23, 2017
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERTIsabelle C Van Gelder, Jeff S Healey, Harry J G M Crijns, et al.
International Journal of Cardiology. Heart & Vasculature|November 30, 2020
Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation - Data from the RACE 3 studyBao Oanh Nguyen, E P J Petra Wijtvliet, Anne H Hobbelt, et al.
European Heart Journal|February 6, 2018
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trialMichiel Rienstra, Anne H Hobbelt, Marco Alings, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 18, 2021
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trialBao Oanh Nguyen, Harry J G M Crijns, Jan G P Tijssen, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 26, 2021
Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 studyMeelad I H Al-Jazairi, Bao-Oanh Nguyen, Ruben R De With, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|January 11, 2019
Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 studyRuben R De With, Michiel Rienstra, Marcelle D Smit, et al.
Pageof 1